VERA THERAPEUTICS INC. - CLASS A COMMON STOCK

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Oct 2024 16:05:00 By Nasdaq GlobeNewswire

Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases

02 Oct 2024 06:30:00 By Nasdaq GlobeNewswire

Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024

02 Oct 2024 06:30:00 By Nasdaq GlobeNewswire

Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024

16 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgAN

12 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 Sep 2024 16:05:00 By Nasdaq GlobeNewswire

Vera Therapeutics to Participate at September Investor Conferences

29 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

09 Aug 2024 16:05:00 By Nasdaq GlobeNewswire

Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

08 Aug 2024 08:00:01 By Nasdaq GlobeNewswire

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Jul 2024 16:30:00 By Nasdaq GlobeNewswire

Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer

01 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

Vera Therapeutics Appoints Christy J. Oliger to Board of Directors

11 Jun 2024 16:01:00 By Nasdaq GlobeNewswire

Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

07 Jun 2024 16:05:00 By Nasdaq GlobeNewswire

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 Jun 2024 16:05:00 By Nasdaq GlobeNewswire

Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)

28 May 2024 08:00:00 By Nasdaq GlobeNewswire

Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress

25 May 2024 09:40:00 By Nasdaq GlobeNewswire

Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

09 May 2024 08:00:01 By Nasdaq GlobeNewswire

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 May 2024 16:38:19 By Nasdaq GlobeNewswire

Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress

02 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

20 Mar 2024 07:30:00 By Nasdaq GlobeNewswire